SYNDROMIC MULTIPLEX DIAGNOSTICS AND PANELS MARKET: Strategies and Trends, Forecasts by Syndrome, Place, Product and Country with Market Analysis, Executive Guides and Customization 2022 to 2026
“The Syndromic Multiplex Diagnostics market enters a new post-pandemic growth phase as new entrants jockey for position in a new diagnostic world…..”
Publication date: April 20, 2022
Page count: 516
The COVID pandemic has ushered in a new world of infectious disease diagnostics. Infectious disease Dx is changing - can an already rapidly growing market expand even faster? Find out all about it in this latest report on Syndromic Multiplex Diagnostics.
Are targeted tests for specific pathogens going to be obsolete?
Syndromic testing is proving itself in the market. players are reporting double-digit growth. Lowering costs, improving outcomes and even helping in the battle against antimicrobial resistance (AMR). The two key trends of point of care (POC) testing and molecular diagnostics (MDx) are meeting with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. Learn about this market including the issues and outlooks.
In a special section the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel-based ordering of infectious disease tests.
The report forecasts the market size out to 2026 and includes detailed breakouts for 14 countries and 5 regions.
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade. We wrote this report and are ready by phone or email to help you use it.
Assistance and additional breakout data relevant to your own area(s) of interest is available free of charge with the report (corporate license).
All report data is available in Excel format on request.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School